FDA accepts Eylea sBLA for Priority Review

• The FDA accepts for Priority Review Regeneron Pharmaceuticals' (NASDAQ:REGN) supplemental biologics license application (sBLA) for Eylea (aflibercept) for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME). The PDUFA date for the Breakthrough Therapy-designated indication is March 30, 2015.
• Elyea is currently approved for the treatment of diabetic macular edema, macular edema following retinal vein occlusion and wet age-related macular degeneration.